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IMMUNOLOGY 
Cracking the immunological code of pregnancy 
Interactions between maternal immune cells and the placenta influence pregnancy complications  
 
By Francesco Colucci 
 
The World Health Organization estimates that 10% of the burden of disease worldwide is due to 
problems that arise during pregnancy which compromise the health of mother and fetus. Genetic, 
endocrine, metabolic, and cardiovascular factors contribute to pregnancy complications, e.g 
spontaneous abortion, pre-eclampsia, fetal growth restriction, preterm labor and still birth. Some of 
these problems are due to placental dysfunction (1). Attaching to and invading deep into the 
specialized uterine mucosa called decidua, which is rich in maternal immune cells, the placenta is the 
fetus’s lifeline. It grows from the blastocyst-derived trophoblast and, once formed, nourishes the fetus 
trough the umbilical cord. Carrying genetic material from another individual (the father), the placenta 
ought to be targeted by the immune system that specializes in detecting and destroying what is 
different from self. Significant pathology, including allergy, autoimmunity, transplant rejection, and 
sepsis is caused by exaggerated, inappropriate, unwanted, or systemic immune responses. Do 
interactions between the placenta and maternal immune system influence pregnancy complications? 
And if we understand these interactions, can we intervene to improve pregnancy outcome? 
 
One well-documented example of how the maternal immune system can cause pathology through 
immunological incompatibility is Rhesus (Rh) disease. Immunity is passed on from mother to fetus 
through special receptors on placental cells that bind antibodies of a specific type (IgG), which are best 
at carrying immunological memory. This arms neonates with their mother’s antibodies, which protect 
infants while they develop their own antibodies but, in pregnant Rh- mothers bearing a Rh+ positive 
fetus, harmful maternal antibodies against incompatible blood groups are also transported through 
the placenta and destroy fetal red blood cells causing severe anemia. Understanding the basic 
mechanisms of this fetal disease has led to a simple and successful preventative strategy based on 
immune intervention.  
 
To understand most pregnancy complications, however, one ought to take a closer look at the 
interactions within the decidua (Figure). Trophoblast invasion into the decidua is a necessary event to 
ensure that the developing embryo taps into nutrients and oxygen available in the maternal blood. The 
concerted effort between maternal decidual cells and fetal trophoblast cells transforms uterine arteries 
into flaccid, large conduits, called spiral arteries, where circulation is slowed down. Appendices of the 
placenta (the villi) bathe in the transformed arteries, both absorbing the necessary nutrients and 
exchanging gases needed for fetal growth. It is when placental invasion is too shallow and arterial 
transformation incomplete that some pregnancy complications arise (1). Progress in obstetrics 
research is hard because of the constantly changing nature of tissues and the difficulty in accessing 
them. Naturally, the placenta is available at term, but key events happen in the first trimester. An 
additional challenge in modern immunology is to decode the function of tissue resident immune cells, 
which despite phenotypic resemblance across organs, may adapt in response to specific 
microenvironments. Moreover, each species has evolved its own way of placentation. Bearing in mind 
the differences in anatomy and reproductive biology, the mouse may be a useful model. The placenta 
in both species is haemochorial, meaning extravillous trophoblast (EVT) cells invade into the decidua in 
both species (Figure), although the degree of invasion is greater in humans. Another similarity between 
human and mouse is that cells of the innate immune system are most abundant in the decidua. These 
include decidual NK cells (dNK) and macrophages, along with dendritic cells (DC) and T cells, including 
regulatory T cells (Tregs) (2). Mouse studies have helped to appreciate the critical role played in 
pregnancy by Tregs, a special population of lymphocytes that suppress immune responses. Tregs are 
induced in the female reproductive tract by cytokines in the seminal plasma, prevent fetal loss, expand 
in subsequent pregnancies, and, in humans, may be at fault in certain pregnancy complications (3). 
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And yet, antigen-specific maternal immune cells that might cause placental dysfunction and must be 
controlled by Tregs, have never been identified. It is possible that the physiological role of decidual 
Tregs is not actually to suppress immune responses. An alternative role for decidual Tregs may be 
tissue homeostasis, as already shown in adipose tissue, muscle, and intestine (4).  
 
Maternal immune cells in the decidua may have adapted to have a physiological function rather than 
specializing in aggressive immunological defense. Immunological mechanisms originally evolved to 
destroy and repair, might have been co-opted to participate to successful placental invasion. 
Inflammation, intended as the stereotypical vascular and cellular adaptations that respond to tissue 
injury by destroying first and repairing after, may well be an intrinsic feature of reproduction, rather 
than being an obstacle. Clearly there are extreme cases when local inflammation caused by infections 
or systemic endothelial responses in pre-eclampsia are unhealthy and can be even fatal to mother or 
fetus. But, operating constantly and independently of conception and implantation, inflammation and 
the innate immune system might have become integral to the necessary destruction and regeneration 
of the uterine mucosa during the menstrual cycle. It is therefore conceivable that the process of 
placental invasion and differentiation have also benefited from the function of the immune system. 
The concept that maternal immune cells must be activated for a healthy pregnancy may be 
counterintuitive to traditional concepts of immunity and pregnancy, which suggest that immunological 
tolerance must prevail and, for the pregnancy to succeed, maternal immune cells must be prevented 
from responding to paternal antigens.  
 
The ultimate example of the need for functional immune cells at the maternal-fetal interface may well 
be dNK cells. While blood NK cells are known for their natural propensity to kill virally-infected and 
cancerous cells, dNK are involved in tissue physiology, rather than in killing. Original observations in 
mice demonstrated indeed that dNK cells are necessary for uterine vascular adaptations during 
pregnancy (5). In both human and mice dNK cells are found in close proximity to both trophoblast at 
sites of invasion and blood vessels. It is reasonable to think that dNK cells in both species participate in 
controlling trophoblast invasion and transforming the uterine blood vessels. Evidence suggests that 
excessive inhibition of dNK cell function impedes full development of the placenta with repercussions 
on fetal growth (6). Maternal dNK cells and trophoblast cells can be seen establishing intimate 
connections. Several receptor-ligand interactions have been decoded that can mediate the dialogue 
between mother and placenta (Figure). Importantly, the main determinants of histocompatibility and 
graft rejection (the extremely variable HLA molecules) are excluded from this dialogue because the 
outer layer of the placenta (syncytiotrophoblast) does not express them, thus avoiding any possible 
recognition by maternal immune cells. EVT however do express polymorphic HLA-C.  All HLA-C 
allotypes can bind polymorphic dNK receptors called KIR, which can be activating or inhibitory. Certain 
combinations of maternal KIR and fetal HLA-C genetic variants are indeed linked to birth weight and 
pregnancy complications (6). Modulation of dNK cells activation by this interaction may sway the 
balance towards too much inhibition or activation. Similar mechanisms seem to operate in mice, where 
dNK cells are key to promoting fetal growth (7). Other receptor-ligand pairs between dNK cells and 
trophoblast may be key to placentation, such as receptors LILRB1 (also expressed on macrophages) 
and NKG2A, which bind respectively to HLA-G and HLA-E. Memory granting us adaptive immunity 
upon infection or vaccination has been thought for decades to be a feature of B and T lymphocytes. It 
has now become apparent, however, that innate immunity also has some form of memory. During 
first-time pregnancies, LILRB1 and NKG2C (also binding HLA-E) may trigger epigenetic DNA 
modifications in some dNK cells, making them potentially more active in subsequent pregnancies (8), 
which are exposed to reduced risk of pre-eclampsia.  
 
The cellular networks operating in the decidua and placenta are starting to be revealed by new 
technology. RNA sequencing in dNK and related innate lymphoid cells in mice has revealed further 
specialization of these cells in the decidua, with potential division of labor and adaptation to the 
different phases of reproductive life (9). Single-cell RNA sequencing of the human maternal-fetal 
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interface has begun to identify cellular and molecular networks that involve decidual stromal cells, 
immune cells, epithelial and endothelial cells, as well as fetal trophoblast and macrophages (10). The 
three subsets of dNK cells identified may well have distinct functions connecting with trophoblast, 
maternal stromal or immune cells (10). Mass cytometry, both on cell suspensions and by imaging may 
well reveal new functional and spatial information on these interactions, because it lends itself to a 
detailed analysis of heterogeneous cell populations. Human trophoblast organoids will help to study 
complex interactions with other cells at the maternal-fetal interface, including immune cells, and in 
defined genetic backgrounds (11). 
 
Maternal and fetal cells in the decidua and placenta don’t operate in isolation. How do nutrition, 
metabolism, and oxygen concentration influence these interactions? Metabolomics analyses of the 
placenta have started to decipher the differences between metabolites in maternal and fetal tissues 
(12) and might eventually integrate our growing appreciation of how metabolism shapes immune 
functions. Do microbes influence immunology of placentation, contributing to pregnancy 
complications? Labor may indeed be precipitated by infections leading to pre-term birth. The history 
of ancestral viral infections that have helped placentation is written in our DNA. Our genomes harbor 
endogenous retroviruses that have helped placental cells to fuse together to form a syncytium. 
Microbes or microbial products living in the mother may influence feto-placental development, and 
some evidence suggests that microbiota in the placenta and amniotic fluid may colonize fetal gut in 
utero (13). However, other findings do not support the existence of a placenta microbiome (14). 
 
Once cellular and molecular networks and the factors that regulate them are identified the next 
challenge will be to understand how they go wrong in pregnancy complications. Are we ready to 
manipulate the human immune system during pregnancy to prevent complications? The short answer 
is not yet. Despite the successful precedent of immune intervention to prevent Rhesus disease for over 
5 decades, one may argue that it may be too risky to interfere with the maternal immune system. 
Currently, anti-inflammatory and immunosuppressive drugs such as aspirin, hydroxycloroquine, and 
steroids are used to improve the outcome of some pregnancy complications like pre-eclampsia, 
antiphospholipid antibodies, chronic villitis or even to improve fertility. The benefit of these treatments 
is generally minimal and, for example in pre-eclampsia, may be confounded by the beneficial effect of 
aspirin on the systemic endothelial response. In modern medicine there is much excitement about the 
power of immune checkpoint inhibitors (ICI) in the treatment of patients with cancer. These 
monoclonal antibodies target inhibitory receptors on lymphocytes and, in a significant number of 
patients, reawake lymphocytes against cancer, improving outcome. Subsets of dNK cells and T cells in 
the decidua have inhibitory receptors that can be targeted by ICI (NKG2A, KIR, TIGIT, TIM-3 on dNK 
cells and CTLA-4 and PD-1 on T cells) and trophoblast cells express ligands for some of these 
receptors, including HLA-E, HLA-C, PVR, and PD-L1 (10). ICI in pregnant mice causes fetal loss.  
However, a patient with melanoma treated with ICI survived and had a favorable pregnancy outcome 
(15), illustrating that the possibility of immune-based interventions at the maternal-fetal interface may 
be explored. With technology advancing fast and by improving our knowledge of both the individual 
uterine immune cells and the function of the whole system, we are starting to crack the unique 
immunological code of pregnancy and may one day intervene to improve outcome.  
 
 





The placenta develops during the first trimester, when trophoblast cells replace the lining of maternal 
arteries, which are transformed into spiral arteries. The syncytiotrophoblast (Syn) that is in direct 
contact with maternal blood does not express MHC molecules and is therefore not recognized by 
maternal immune cells. Fetal extravillous trophoblast (EVT) bud off the villi and interact with maternal 
immune cells. Some of the molecular interactions between macrophages, dNK cells, dendritic cells and 
fetal EVT are indicated. Decoding the nature of these interactions and how they affect placental 
development my help to understand the cause of some pregnancy complications. Modified from 
Robbins JR, Skrzypczynska KM, Zeldovich VB, Kapidzic M, Bakardjiev AI (2010) Placental 
Syncytiotrophoblast Constitutes a Major Barrier to Vertical Transmission of Listeria monocytogenes. 
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